Search

We report the lightfastness of deuterated and undeuterated ultraviolet absorbers (UVAs). The durability of following species: 2-phenylpyridine (1H, 1D); 2,2'-bipyridine (2H, 2D); benzophenone (3H, 3D); phenylbenzoate (4H, 4D); 2-(2-benzotriazolyl)-p-cresol (5H, 5D) has been evaluated under UV light (254 or 355 nm) irradiation by means of UV-vis photoabsorption spectrometry. While all these compounds show a low photoreaction quantum yield ( 10-6 to 10-4), each deuterium labeled substance has a 1.2-1.5 times longer lifetime compared to the unlabeled one. Lightfastness of UVAs can be increased by deuteration through a positive isotope effect without changing its photo absorption wavelength and molecular extinction coefficient. [ABSTRACT FROM AUTHOR]

The endocrine-disrupting activities of various environmental chemicals are metabolically activated. For example, diphenyls, styrene oligomers, chalcones, trans-stilbene and 2-nitrofluorene are not estrogens, but after incubation with liver microsomes, their metabolites show estrogenic activities. Thus, these chemicals are estrogenically activated by the cytochrome P450 system. In contrast, the antiandrogenic activity of fenthion, an organophosphorus insecticide, is abolished after metabolism to sulfoxide and sulfone derivatives. Structural requirements of twenty bisphenol A related compounds, as well as various benzophenones, for estrogenic and antiandrogenic activities have been investigated. The estrogenic and antiandrogenic activities of Benzophenone 3, a representative UV absorbant, are activated by oxidative metabolism. Parabens (used as antimicrobial agents) exhibit estrogenic activity, and their potency shows a bell-shaped curve between C1 (methylparaben) and C12 (dodecylparaben) parabens. The AhR ligand activity of indirubin is decreased by metabolism. Polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDE) are activated by hydroxylation to show estrogenic and thyroid hormone-disrupting activities. Halogen adjacent to a hydroxyl group is essential for thyroid hormone-disrupting activity. Tetrabromobisphenol A, tetrachlorobisphenol A and tetramethylbisphenol A also exhibit thyroid hormone-disrupting activity. Amphibian metamorphosis of tadpoles to frogs is affected by hydroxylated PCB, hydroxylated PBDE and bisphenol A derivatives. These chemicals suppress thyroid hormone-dependent metamorphosis, acting as antagonists of thyroid hormone. Thus, metabolic modification can have a dramatic impact on the endocrine-disrupting activities of environmental chemicals.

In order to verify the safety associated with reusing PET and glass bottles, a challenge test was conducted with five surrogate contaminants: 1,1,1-trichloroethane, chlorobenzene, toluene, benzophenone and phenyl cyclohexane. Bottles were filled with a cocktail solution of these contaminants and stored at 50 °C for 7 days, then washed with water and alkaline solutions. Material and migration tests were conducted at each step. The material test results showed that 430-1,440 µg/g of the contaminants were retained after water washing, and that even after washing with a 3.5% NaOH solution, 225-925 µg/g of the contaminants were retained. The migration tests revealed that 0.095-7.35 µg/mL of the contaminants were eluted. Similar tests were conducted with a soft drink ingredient, limonene. The results revealed that 48 µg/g of limonene was retained even after washing with NaOH solution, and that 0.16 µg/mL of limonene was eluted. Conversely, no contaminants were eluted from glass bottles after washing with the NaOH solution. Thus, from the viewpoint of safety and the preservation of content quality, PET bottles are not considered suitable for reuse when compared with glass bottles.

Antiparkinsonian agents applied or under the investigation for the treatment of patients with Parkinson's disease were reviewed. Tremor, akinesia, rigidity and postual instability are key signs of Parkinson's disease. The most important one is akinesia, which includes decreased spontaneous locomotor activity, slowness of movement, awkwardness and freezing. The main pathophysiology of Parkinson's disease is neurodegeneration of nigrostriatal dopaminergic neurons. Neurotoxins or oxidative stress to the dopaminergic neurons have been discussed as one of the etiologies of degeneration. Antioxidant or neuroprotective agents will be the future drugs for Parkinson's disease. At present, supplement of dopamine by levodopa administration, retarding the metabolism of levodopa or dopamine by a dopa decarboxylase inhibitor (DCI), MAO-B (monoamine oxidase inhibitor type B) inhibitor or catechol-O-methyltransferase (COMT) inhibitor, dopamine receptor agonists, anticholinergic agents, dopamine release enhancer/uptake inhibitor, N-methyl-D-aspartate (NMDA) receptor antagonists are applied for the treatment of Parkinson's disease. New agents such as adenosine receptor antagonists, serotonergic agents and nicotinic receptor agonists are under investigation. Agents to facilitate the growth of nerves or to inhibit degeneration of nerves are also studied and will be developed for the treatment of Parkinson's disease in the future. In the case of familial Parkinson's disease, abnormal genes were identified. Gene therapy might be another future treatment for these cases.